UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 309

Sortiert nach

A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma

Clinical cancer research, 2014-12, Vol.20 (24), p.6304-6313

2014

Link zum Volltext

Verfügbarkeit prüfen

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients

Pharmaceutics, 2019-04, Vol.11 (4), p.152

2019

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

Molecular cancer research, 2018-05, Vol.16 (5), p.767-776

2018

Link zum Volltext

Verfügbarkeit prüfen

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity

Frontiers in oncology, 2018-09, Vol.8, p.387-387

2018

Link zum Volltext

Verfügbarkeit prüfen

HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality

Journal for immunotherapy of cancer, 2019-07, Vol.7 (1), p.191-191, Article 191

2019

Link zum Volltext

Verfügbarkeit prüfen

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial

Cancer treatment and research communications, 2021, Vol.28, p.100427-100427, Article 100427

2021

Link zum Volltext

Verfügbarkeit prüfen

Aphorismus

Fricke, Harald

1st edition., 2016

Link zum Volltext

Verfügbarkeit prüfen

Aphorismus

Fricke, Harald

1, 1984

Link zum Volltext

Verfügbarkeit prüfen

Correlates of local cerebral blood flow (CBF) in normal pressure hydrocephalus patients before and after shunting : A retrospective analysis of [15O]H2O PET-CBF studies in 65 patients

Clinical neurology and neurosurgery, 2008-04, Vol.110 (4), p.369-375

2008

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients

Journal of neuro-oncology, 2019-12, Vol.145 (3), p.531-540

2019

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2022-2022

2019

Link zum Volltext

Verfügbarkeit prüfen

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors

Molecular cancer therapeutics, 2013-12, Vol.12 (12), p.2735-2747

2013

Link zum Volltext

Verfügbarkeit prüfen

Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro

Anti-cancer drugs, 2015-08, Vol.26 (7), p.716-727

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1760: The hexavalent CD40 agonist HERA-CD40L augments multi-level crosstalk between T cells and antigen-presenting cells

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1760-1760

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 464: Methylation of a single CpG site in the CD95-ligand promoter is a biomarker predicting the response to therapy with APG101 in glioblastoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.464-464

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1688: HERA-CD40L: A novel hexavalent CD40 agonist with superior biological activity

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1688-1688

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3754: The novel hexavalent human CD137/4-1BB agonist HERA-CD137L promotes anti-cancer immunity by activating CD8 T cells while regulatory T cells are not affected

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3754-3754

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 630: Novel hexavalent HVEM agonist HERA-LIGHT promotes T cell activation and expansion

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.630-630

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4845: HERA-CD27L, a true CD27 agonist, is a hexavalent CD27 ligand that enhances T cell activation and induces potent anti-tumor immunity

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4845-4845

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5015: HERA-CD40L a hexavalent CD40 agonist induces T cell mediated anti-tumor immune response and shows superior activity in direct comparison to benchmark agonistic antibodies

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.5015-5015

2019

Link zum Volltext

Verfügbarkeit prüfen

Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer

International journal of colorectal disease, 2012-10, Vol.27 (10), p.1369-1376

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract A115: The CD95 ligand inhibitor APG 101 reduces tumor recurrence and metastasis in an adjuvant orthotopic mouse model of pancreatic cancer as well as primary tumor load in a palliative setting

Cancer research (Chicago, Ill.), 2015-07, Vol.75 (13_Supplement), p.A115-A115

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1204: A construction platform for hexavalent agonists targeting receptors of the tumor necrosis factor superfamily: Where death meets co-stimulation

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1204-1204

2016

Link zum Volltext

Verfügbarkeit prüfen

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells

Cell death & disease, 2018-04, Vol.9 (5), p.445-15, Article 445

2018

Link zum Volltext

Verfügbarkeit prüfen

High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis

American journal of nephrology, 1996-01, Vol.16 (6), p.484

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 309

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(227)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(63)
Humans
(55)
Art Exhibits
(39)
Female
(34)
Arts & Humanities
(33)
Visual Artists
(32)
Male
(31)
Biological And Medical Sciences
(29)
Middle Aged
(28)
Medical Sciences
(26)
Aged
(22)
Adult
(20)
Literary Studies: General
(13)
Oncology
(12)
Literature: History & Criticism
(11)
Animals
(10)
Immunology
(10)
Radiology, Nuclear Medicine & Medical Imaging
(10)
Exhibitions
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity

HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial

Aphorismus

Aphorismus

Correlates of local cerebral blood flow (CBF) in normal pressure hydrocephalus patients before and after shunting : A retrospective analysis of [15O]H2O PET-CBF studies in 65 patients

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients

Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors

Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro

Abstract 1760: The hexavalent CD40 agonist HERA-CD40L augments multi-level crosstalk between T cells and antigen-presenting cells

Abstract 464: Methylation of a single CpG site in the CD95-ligand promoter is a biomarker predicting the response to therapy with APG101 in glioblastoma

Abstract 1688: HERA-CD40L: A novel hexavalent CD40 agonist with superior biological activity

Abstract 3754: The novel hexavalent human CD137/4-1BB agonist HERA-CD137L promotes anti-cancer immunity by activating CD8 T cells while regulatory T cells are not affected

Abstract 630: Novel hexavalent HVEM agonist HERA-LIGHT promotes T cell activation and expansion

Abstract 4845: HERA-CD27L, a true CD27 agonist, is a hexavalent CD27 ligand that enhances T cell activation and induces potent anti-tumor immunity

Abstract 5015: HERA-CD40L a hexavalent CD40 agonist induces T cell mediated anti-tumor immune response and shows superior activity in direct comparison to benchmark agonistic antibodies

Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer

Abstract A115: The CD95 ligand inhibitor APG 101 reduces tumor recurrence and metastasis in an adjuvant orthotopic mouse model of pancreatic cancer as well as primary tumor load in a palliative setting

Abstract 1204: A construction platform for hexavalent agonists targeting receptors of the tumor necrosis factor superfamily: Where death meets co-stimulation

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells

High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis

Suchergebnisse filtern